India Pharma Outlook Team | Monday, 06 July 2026
Granules India has achieved a significant regulatory milestone by securing First-to-File (FTF) status in the US for the generic version of Lumryz, a drug used to treat narcolepsy.
The company filed an Abbreviated New Drug Application (ANDA) with Paragraph IV certification, positioning it as the first applicant for the product. If all regulatory conditions are met, then the generic receives final approval, Granules India could be eligible for 180 days of marketing exclusively in the US.
This exclusivity offers a valuable commercial advantage, allowing the company to market the generic product without direct generic competition for six months. The achievement also reflects the company's growing focus on complex and differentiated products. That is likely to offer higher entry barriers and stronger long-term growth opportunities than conventional generic medicines.
Lumryz is an extended release formulation of sodium oxybate used for the treatment of narcolepsy. It is a chronic neurological disorder that affects the brain's ability to regulate sleep and wake cycles. Patients with narcolepsy often experience excessive daytime sleepiness and sudden episodes of muscle weakness known as cataplexy.
Unlike conventional medicines, these extended release formulations require sophisticated drug delivery technologies and rigorous manufacturing standards. These characteristics place Lumryz among complex generic drugs. Where only a limited number of manufacturers possess the scientific expertise and regulatory capability required for development.
Success in these products demonstrates the increasing technical strength of Indian pharmaceutical companies. As global healthcare systems continue to seek affordable alternatives to branded specialty medicines, Indian manufacturers are steadily expanding beyond traditional generics.
Also Read: Pharmaceutical 4.0: Redefines Compliance, Automation & AI
Granules India's regulatory success is an indicator of India's evolving role in the global pharmaceutical industry. Indian companies have been recognized as leading suppliers of affordable generic medicines. But in recent years, a strategic shift towards complex generics is seen in specialty products and value-added formulations.
Developing complex generics not only enhances export opportunities but also improves the industry's global competitiveness by showcasing advanced research, development, and manufacturing capabilities.
“Securing sole first-to-file for our sodium oxybate extended release for oral suspension ANDA is another important milestone in our complex generics journey”, said by Dr. Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India.
Regulatory achievements such as FTF status reinforce India's reputation as a trusted supplier of high-quality medicines. Although Lumryz is currently targeted at the US market, expanding expertise in complex drug development can ultimately benefit Indian patients as well.
As domestic companies gain experience with advanced formulations, they are better positioned to introduce innovative and more affordable treatment options in India. This supports broader efforts to improve access to specialized therapies for patients with rare and chronic diseases.
Granules India Limited is a Hyderabad-based pharmaceutical company that specializes in active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages. The company supplies medicines to more than 80 countries and has expanded its portfolio of complex generic and specialty pharmaceutical products.
.jpg)
